Once the company announce on the details of privatisation. It will cross the 0.70 barrier. Can slowly to collect by tomorrow for some study pocket money.
LTAT holds 60%, KWAP 10%, KWSP 5%, other related Glic 5%, unit trusts and IB s another 5-6 %0. Total already 85. Free float 15 % balance. Easily take private if Go ahead
An analyst with a local research firm says Boustead’s stock has been trending downwards, from RM3 in October 2017 to as low as 35 sen in March this year, before rebounding to 63 sen last Thursday. Assuming an investor bought 1,000 Boustead shares at RM3 per share and is still holding the shares today, he would be sitting on a paper loss of RM2,370.
“This perhaps reflects the deteriorating fundamentals of the group, which has been making losses since the financial year ended Dec 31, 2018 (FY2018). On the other hand, the indicative offer price of 80 sen represents a steep discount to the latest book value per share of RM1.85, which, of course, would erode further if the losses persist,” he tells The Edge.
“Therefore, in the short term, the offer price seems reasonable, given the limited potential upside amid the weak fundamentals. But in the longer run, if Boustead is able to turn around its fortunes, the stock may be worth more than 80 sen per share,” the analyst notes.
“There are pros and cons for a company to be listed or taken private. In this case, if LTAT has big plans to overhaul Boustead with restructuring measures that may lead to more short-term pain, it will be easier to implement the plan as a private entity. On the other hand, if they want the flexibility for Boustead to raise funds from the capital market, then Boustead should remain listed,” he adds.
While LTAT did not disclose the reason for seeking to take the group private, Boustead’s stock valuations remain depressed. Its shares have lost 44% of their value in the last 12 months versus the FBM KLCI’s decline of 10%.
While depressed valuations might be an attractive reason for LTAT to take Boustead private, the move might not be the best from the point of view of minority shareholders, given the 57% discount to Boustead’s book value of RM1.85 as at Dec 31, 2019.
Bursa Malaysia filings show that Kumpulan Wang Persaraan (Diperbadankan) (KWAP) and the Employees Provident Fund (EPF) Board are Boustead’s second and third largest shareholders, holding 9.19% and 4.99% respectively.
The analyst believes that whether Boustead’s existing shareholders would be willing to let go of their stake would depend on internal considerations of factors such as their holding period and whether they are able to find better investment opportunities elsewhere. “Interestingly, the EPF sold some shares last December and early January when Boustead’s share price was hovering around 90 sen to RM1,” he says.
Kenanga Research says it was not overly surprised by LTAT’s proposal to take Boustead private, considering that the latter has been facing mounting debts and losses over the past few years.
The research firm estimates that the privatisation would cost Boustead’s major shareholder RM658 million, assuming that this takeover is subject to the Securities Commission Malaysia waiving the mandatory general offers that this may trigger on other listed units that the group owns.
Boustead has three listed companies under its stable — Boustead Heavy Industries Corp Bhd (BHIC), Pharmaniaga Bhd and Boustead Plantations Bhd, with a shareholding of 65%, 56.09% and 57.42% respectively. It also holds a 20.76% stake in Affin Bank Bhd.
“At an indicative 80 sen per share, the privatisation works out to 0.48 times FY2019 net tangible assets of RM1.66 per share, which is lower than its historical average of 1.1 times,” Kenanga Research said in a note to clients last Friday.
The privatisation would also help LTAT restructure its businesses outside the scrutiny of public shareholders and regulators. The fund recently embarked on its overall transformation journey under its five-year strategic plan beginning 2019, while Boustead is undergoing its own turnaround programme.
Last year, LTAT’s performance was impacted primarily as no dividends were declared by Boustead and Affin Bank, compared with RM124.2 million in dividends received in FY2018. The fund was only able to announce better dividends in FY2019 of 2.5% compared with FY2018’s 2% as a result of a waiver from paying dividends on the government’s contribution to the fund for FY2019.
The past two years, however, have also been tumultuous for Boustead. Dividends have not been forthcoming as the group has not been making a profit since FY2018, impacted by losses and impairments incurred in the heavy industries and plantation divisions.
The group widened its net loss to RM1.28 billion in FY2019 from RM554.3 million the previous year, after taking an impairment charge of RM1.33 billion for its assets from the heavy industries and plantation segments. In addition, the pharmaceutical division was affected due to recognition of the remaining unamortised Pharmacy Information System costs amounting to RM247 million. Revenue rose by a marginal 1.4% year on year to RM10.33 billion.
Don't worry about this company as LTAT would let it burst. Slowly collect in batch once hit 0.60 ! No issue to make profit and minority will agree to accept once price is lower.
bhic has return to black and awarded new contract, pharmaniaga will be in good earnings rest of the year due to covid, bplant 50:50 in recovery but sure on better side
>rm1 next year not impossible
even if not rm1, 80c take over very good as my ave is 63c
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
setia2u
971 posts
Posted by setia2u > 2020-06-08 19:46 | Report Abuse
Why giving out 1,85 when you just need to give 80 sen and keep the 1.05?